Boston Millennia Partners Intends to Vote Against Proposed Merger of SomaLogic With Standard BioTools

12/31/23 2:10:00 PM ET

$LAB

$SLGC

Biotechnology: Laboratory Analytical Instruments

Industrials

Biotechnology: Commercial Physical & Biological Resarch

Health Care

Get the next $LAB alert in real time by email

Boston Millennia Partners ("Boston Millennia"), a significant shareholder of SomaLogic (the "Company") (NASDAQ:SLGC) today announced that it intends to vote against the Company's planned merger (the "Merger") with Standard BioTools Inc. (NASDAQ:LAB).

View source version on businesswire.com: https://www.businesswire.com/news/home/20231231077712/en/

Get the next $LAB alert in real time by email

Crush Q3 2025 with the Best AI Superconnector

Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

AI-Powered Inbox

Context-aware email replies

Strategic Decision Support

Get Started with Standout.work

Recent Analyst Ratings for
$LAB
$SLGC

Company	Date	Price Target	Rating	Analyst
Standard BioTools Inc. $LAB	8/13/2025	$1.55	Buy → Hold	TD Cowen
Standard BioTools Inc. $LAB	2/27/2025		Overweight → Sector Weight	KeyBanc Capital Markets
Standard BioTools Inc. $LAB	4/16/2024	$3.50	Buy	TD Cowen
Standard BioTools Inc. $LAB	4/4/2024	$3.25	Buy	Jefferies
SomaLogic Inc. $SLGC	10/5/2023	$3.50 → $2.29	Buy → Hold	Jefferies
SomaLogic Inc. $SLGC	9/25/2023	$5.00 → $2.50	Buy → Hold	Canaccord Genuity
Standard BioTools Inc. $LAB	7/12/2023	$4.00	Overweight	KeyBanc Capital Markets
SomaLogic Inc. $SLGC	2/1/2022	$12.00	Buy	Stifel

More analyst ratings

Boston Millennia Partners Intends to Vote Against Proposed Merger of SomaLogic With Standard BioTools

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$LAB
$SLGC

Boston Millennia Partners Intends to Vote Against Proposed Merger of SomaLogic With Standard BioTools

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$LAB
$SLGC

$LAB
$SLGC
Insider Trading

Director Casdin Partners Master Fund, L.P. bought $443,033 worth of shares (358,220 units at $1.24) (SEC Form 4)

Chief Financial Officer Kim Hanjoon Alex was granted 1,500,000 shares, increasing direct ownership by 159% to 2,440,564 units (SEC Form 4)

President & CEO Egholm Michael was granted 3,000,000 shares, increasing direct ownership by 110% to 5,736,285 units (SEC Form 4)

$LAB
$SLGC
Press Releases

Standard BioTools Reports Second Quarter 2025 Financial Results

Standard BioTools and Precision Health Research, Singapore (PRECISE-SG100K) Launch Proteomics Collaboration, Selecting SomaScan to Power Large-Scale Population Health Study

Standard BioTools Schedules Second Quarter Earnings Conference Call on August 11, 2025

$LAB
$SLGC
SEC Filings

SEC Form S-8 filed by Standard BioTools Inc.

SEC Form 10-Q filed by Standard BioTools Inc.

SEC Form NT 10-Q filed by Standard BioTools Inc.

$LAB
$SLGC
Analyst Ratings

Standard BioTools downgraded by TD Cowen with a new price target

Standard BioTools downgraded by KeyBanc Capital Markets

TD Cowen initiated coverage on Standard BioTools with a new price target

$LAB
$SLGC
Insider Purchases

Director Casdin Partners Master Fund, L.P. bought $443,033 worth of shares (358,220 units at $1.24) (SEC Form 4)

Director Casdin Partners Master Fund, L.P. disposed of $580,425 worth of shares (545,000 units at $1.06), was granted 58,215 shares, bought $5,134,321 worth of shares (4,820,959 units at $1.06) and acquired $580,425 worth of shares (545,000 units at $1.06) (SEC Form 4)

Director Casdin Partners Master Fund, L.P. bought $546,750 worth of shares (250,000 units at $2.19) (SEC Form 4)

$LAB
$SLGC
Financials

Standard BioTools Reports Second Quarter 2025 Financial Results

Standard BioTools Schedules Second Quarter Earnings Conference Call on August 11, 2025

Standard BioTools Reports First Quarter 2025 Financial Results

$LAB
$SLGC
Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Standard BioTools Inc.

Amendment: SEC Form SC 13G/A filed by Standard BioTools Inc.

Amendment: SEC Form SC 13G/A filed by Standard BioTools Inc.

$LAB
$SLGC
Leadership Updates

Standard BioTools Appoints Alex Kim as Chief Financial Officer

Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company's Proposed Merger with Standard BioTools

SomaLogic Announces Chief Financial Officer Transition

Boston Millennia Partners Intends to Vote Against Proposed Merger of SomaLogic With Standard BioTools

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for $LAB$SLGC

Boston Millennia Partners Intends to Vote Against Proposed Merger of SomaLogic With Standard BioTools

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for $LAB$SLGC

$LAB$SLGC Insider Trading

Director Casdin Partners Master Fund, L.P. bought $443,033 worth of shares (358,220 units at $1.24) (SEC Form 4)

Chief Financial Officer Kim Hanjoon Alex was granted 1,500,000 shares, increasing direct ownership by 159% to 2,440,564 units (SEC Form 4)

President & CEO Egholm Michael was granted 3,000,000 shares, increasing direct ownership by 110% to 5,736,285 units (SEC Form 4)

$LAB$SLGC Press Releases

Standard BioTools Reports Second Quarter 2025 Financial Results

Standard BioTools and Precision Health Research, Singapore (PRECISE-SG100K) Launch Proteomics Collaboration, Selecting SomaScan to Power Large-Scale Population Health Study

Standard BioTools Schedules Second Quarter Earnings Conference Call on August 11, 2025

$LAB$SLGC SEC Filings

SEC Form S-8 filed by Standard BioTools Inc.

SEC Form 10-Q filed by Standard BioTools Inc.

SEC Form NT 10-Q filed by Standard BioTools Inc.

$LAB$SLGC Analyst Ratings

Standard BioTools downgraded by TD Cowen with a new price target

Standard BioTools downgraded by KeyBanc Capital Markets

TD Cowen initiated coverage on Standard BioTools with a new price target

$LAB$SLGC Insider Purchases

Director Casdin Partners Master Fund, L.P. bought $443,033 worth of shares (358,220 units at $1.24) (SEC Form 4)

Director Casdin Partners Master Fund, L.P. disposed of $580,425 worth of shares (545,000 units at $1.06), was granted 58,215 shares, bought $5,134,321 worth of shares (4,820,959 units at $1.06) and acquired $580,425 worth of shares (545,000 units at $1.06) (SEC Form 4)

Director Casdin Partners Master Fund, L.P. bought $546,750 worth of shares (250,000 units at $2.19) (SEC Form 4)

$LAB$SLGC Financials

Standard BioTools Reports Second Quarter 2025 Financial Results

Standard BioTools Schedules Second Quarter Earnings Conference Call on August 11, 2025

Standard BioTools Reports First Quarter 2025 Financial Results

$LAB$SLGC Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Standard BioTools Inc.

Amendment: SEC Form SC 13G/A filed by Standard BioTools Inc.

Amendment: SEC Form SC 13G/A filed by Standard BioTools Inc.

$LAB$SLGC Leadership Updates

Standard BioTools Appoints Alex Kim as Chief Financial Officer

Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company's Proposed Merger with Standard BioTools

SomaLogic Announces Chief Financial Officer Transition

Recent Analyst Ratings for
$LAB
$SLGC

Recent Analyst Ratings for
$LAB
$SLGC

$LAB
$SLGC
Insider Trading

$LAB
$SLGC
Press Releases

$LAB
$SLGC
SEC Filings

$LAB
$SLGC
Analyst Ratings

$LAB
$SLGC
Insider Purchases

$LAB
$SLGC
Financials

$LAB
$SLGC
Large Ownership Changes

$LAB
$SLGC
Leadership Updates